表紙
市場調査レポート

痛覚過敏症:パイプライン分析

Hyperalgesia - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 293882
出版日 ページ情報 英文 35 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
痛覚過敏症:パイプライン分析 Hyperalgesia - Pipeline Review, H1 2016
出版日: 2016年02月24日 ページ情報: 英文 35 Pages
概要

痛覚過敏症は疼痛反応の増大です。素因には長期間のオピオイド利用、炎症、侵害受容体の損傷、末梢神経の損傷および精神的疾患などが含まれます。治療には抗うつ薬および非ステロイド系抗炎症薬が用いられます。

当レポートでは、痛覚過敏症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、および薬剤のプロファイルなどについて、体系的な情報を提供しています。

目次

イントロダクション

痛覚過敏症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

開発中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 初期段階の製品

開発中の製品:企業別

開発中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Cara Therapeutics, Inc.
  • 塩野義製薬

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • AX-007
  • BAM-822
  • CR-701
  • GERPOOI
  • ketoprofen
  • LASSBio-873
  • Recombinant Protein to Activate IL-4 and IL-10 Receptors for Osteoarthritis and CNS
  • Small Molecule to Antagonize P2X3 Receptor for Hyperalgesia

最新パイプライン動向

休止状態のプロジェクト

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7583IDB

Summary

Global Markets Direct's, 'Hyperalgesia - Pipeline Review, H1 2016', provides an overview of the Hyperalgesia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hyperalgesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperalgesia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hyperalgesia
  • The report reviews pipeline therapeutics for Hyperalgesia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hyperalgesia therapeutics and enlists all their major and minor projects
  • The report assesses Hyperalgesia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hyperalgesia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hyperalgesia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hyperalgesia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hyperalgesia Overview
  • Therapeutics Development
    • Pipeline Products for Hyperalgesia - Overview
    • Pipeline Products for Hyperalgesia - Comparative Analysis
  • Hyperalgesia - Therapeutics under Development by Companies
  • Hyperalgesia - Therapeutics under Investigation by Universities/Institutes
  • Hyperalgesia - Pipeline Products Glance
    • Early Stage Products
  • Hyperalgesia - Products under Development by Companies
  • Hyperalgesia - Products under Investigation by Universities/Institutes
  • Hyperalgesia - Companies Involved in Therapeutics Development
    • Cara Therapeutics, Inc.
    • Shionogi & Co., Ltd.
  • Hyperalgesia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AX-007 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BAM-822 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CR-701 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GERPOOI - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ketoprofen - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LASSBio-873 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize P2X3 Receptor for Hyperalgesia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hyperalgesia - Recent Pipeline Updates
  • Hyperalgesia - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hyperalgesia, H1 2016
  • Number of Products under Development for Hyperalgesia - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Hyperalgesia - Pipeline by Cara Therapeutics, Inc., H1 2016
  • Hyperalgesia - Pipeline by Shionogi & Co., Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Hyperalgesia Therapeutics - Recent Pipeline Updates, H1 2016
  • Hyperalgesia - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Hyperalgesia - Comparative Analysis, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top